Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies
NCT03125577Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR19, 4SCAR20, 4SCAR22, 4SCAR30, 4SCAR38 in B cell malignancies, sponsored by Shenzhen Geno-Immune Medical Institute. Started Aug 2025; status: terminated.
02
Drugs
4SCAR194SCAR204SCAR224SCAR304SCAR38
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT03125577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125577.